Professional Documents
Culture Documents
www.uptodate.com
Last literature review version 17.1: January 2009 | This topic last updated: December 31,
2008 (More)
Hematocrit (HCT) is the percent of a sample of whole blood occupied by intact red
blood cells ( show picture 1 ).
RBC count is the number of red blood cells contained in a specified volume of whole
blood, usually expressed as millions of red blood cells per microL of whole blood.
This topic review will provide an approach to the anemic patient. The first portion is
devoted to an understanding of the basic aspects of erythropoiesis and a review of the
causes and clinical consequences of anemia. The second portion is devoted to the clinical
and laboratory evaluation of the anemic patient. An approach to the child with anemia is
presented separately. ( See "Approach to the child with anemia" ).
An introduction to the phenomenon of RBC destruction (hemolysis) and tests which may
be used to provide a diagnosis of hemolytic anemia is presented separately. ( See
"Approach to the diagnosis of hemolytic anemia in the adult" ).
DEFINITIONS
Normal range — One set of "normal ranges" (95 percent confidence limits) for HGB, HCT,
and RBC count is shown in the table ( show table 1 ). If anemia is defined as values which
are more than two standard deviations (SD) below the mean, then, by using these
ranges, a HGB <13.5 g/dL or a HCT <41.0 percent represents anemia in men and a value
<12.0 g/dL or <36.0 percent, respectively, represents anemia in women. Normal ranges
other than the above have been proposed:
Other authors have proposed different lower limits of normal, ranging from 13.0 to
14.2 g/dL for men and 11.6 to 12.3 g/dL for women [ 1] .
WHO criteria for anemia in men and women are <13 and <12 g/dL, respectively [ 2]
. These criteria were meant to be used within the context of international nutrition
studies, and were not initially designed to serve as "gold standards" for the
diagnosis of anemia [ 1] .
diagnosis of anemia [ 1] .
The revised WHO/National Cancer Institute's criteria for anemia in men and women
are <14 and <12 g/dL, respectively [ 3] . These values are meant to be used for
evaluation of anemia in patients with malignancy.
Other lower limits according to sex, age, and race, based on data from NHANES III
and Scripps-Kaiser studies, have been proposed ( show table 2 ) [ 1] . These values
are as low as 12.7 g/dL for black men >60 years of age and 11.5 g/dL for black
women >20 years of age.
There are a number of immediate limitations to this approach:
The above ranges may be "two-tailed" to be used for defining both anemia and
polycythemia. In such cases, 2.5 percent of normal adults will have values which are
more than 2 standard deviations below whatever "normal range" has been selected,
and will be considered anemic. On the other hand, some ranges are "one-tailed",
such that 5 percent of normal subjects will have levels below the stated lower limit
of normal [ 1] .
The normal range for HGB and HCT is so wide that, for example, a male patient
with a baseline HCT of 49 percent may lose up to 15 percent of his RBC mass and
still have a HCT within the normal range.
"Normal" ranges may not apply to special populations (eg, high altitude living,
smokers, athletes, elderly, use of ACE inhibitors). ( See "Special populations" below
and see "Impact of anemia in patients with heart failure" , section on Etiology).
Setting a lower limit of normal for hemoglobin does not imply that such levels are
"optimal" in terms of morbidity and mortality. One study has suggested that the
lower limits of an optimal hemoglobin level, as assessed by all-cause mortality
data, are 13.0 and 14.0 g/dL for elderly women and men, respectively [ 4] .
However, in one study, older black subjects classified as anemic by WHO criteria did
not appear to be at risk for adverse events such as mortality and mobility disability
[5] , suggesting that alternative criteria for anemia are indeed required for this
group ( show table 2 ) [ 1] .
Volume status — HGB, HCT, and RBC count are all concentrations and dependent on the
red blood cell mass (RCM) as well as the plasma volume. As a result, values will be
reduced if the RCM is decreased and/or if the plasma volume is increased [ 6] . Three
common clinical examples will help make this point:
A 70 kg adult with a bleeding peptic ulcer who had a 750 mL hematemesis (ie, 15
percent of a normal total blood volume) within the past 30 minutes may have
postural hypotension due to acute volume depletion, but will have normal values for
HGB and HCT. Over the ensuing 36 to 48 hours, most of the total blood volume
deficit will be repaired by the movement of fluid from the extravascular into the
intravascular space. Only at these later times will the HGB and HCT reflect blood
loss. However, if the total blood volume deficit is not fully repaired and the patient
remains hypovolemic, the HGB and HCT will underestimate the degree of blood loss
[7] .
In the third trimester of pregnancy the RBC mass and plasma volume are
expanded by 25 and 50 percent, respectively, resulting in reductions in HGB, HCT,
and RBC count, often to anemic levels ( show figure 1 ). However, according to the
RBC mass, such women are polycythemic. The terms "physiologic" or "dilutional"
anemia have been applied to this setting.
Patients admitted to the hospital in a volume depleted state may not show
abnormally low HGB/HCT values on initial testing. An underlying anemia may
become apparent only after the volume depletion has been corrected.
Special populations — Normal ranges ( show table 1 ) may not be appropriate for all
populations:
Patients living at high altitude have values higher than those living at sea level [ 8]
. ( See "High altitude and heart disease" , section on Long-term altitude exposure).
A study of blood donors who smoke found a significant and direct correlation
between the patients' blood carboxyhemoglobin and HGB values [ 9] . The same
study also found a significant relationship, although of lesser magnitude, between
HGB values and the degree of environmental air pollution with carbon monoxide in
nonsmoking blood donors. Thus, patients who smoke or have significant exposure
to secondary smoke or other sources of carbon monoxide may have hematocrits
higher than normal [ 10 ] , occasionally reaching polycythemic levels. ( See
"Diagnostic approach to the patient with polycythemia" , section on Acquired
secondary erythrocytosis).
Values for HGB in African-Americans of both sexes and all ages are 0.5 to 1.0 g/dL
lower than values in comparable Caucasian populations [ 1,11-15 ] . Some, but not
all, of these differences may be attributable to co-existing iron deficiency anemia
and/or alpha thalassemia [ 16 ] .
Normal values for a population with a high incidence of chronic disease may be
skewed toward anemic levels. Thus, anemia may be difficult to define in countries
in which malnutrition, infection (eg, tuberculosis, malaria), and/or congenital
hematologic disorders (eg, thalassemia) are common. ( See "Community public
health issues and the thalassemic syndromes: Lessons from other countries" ,
section on Introduction).
The elderly — Values for HGB and HCT in apparently healthy older adults are generally
lower than those in younger adults, and differences between males and females in HGB
and HCT that are seen in younger adults are lessened with aging [ 17-19 ] . The
prevalence of anemia in adults >65 and ≥ 85 years of age has been estimated at 10 and
>20 percent, respectively [ 20,21 ] . As an example, anemia as defined by the WHO
criteria, was present in 26 percent of a cohort of 85 year old adults [ 22 ] .
Although low hemoglobin concentrations are common in older adults, it has been
suggested that the elderly should NOT be presumed to have a lower "normal" range, for
fear of missing a serious underlying disorder [ 20,23-28 ] . A number of large studies have
shown the adverse effects (eg, decline in physical performance, morbidity, mortality) of
anemia in elderly patients [ 4,14,25,26,29-31 ] . Three of these are outlined below:
In 686 community-dwelling women ≥ 65 with self-reported disabilities, HGB levels
progressively lower than 11.0 g/dL were associated with increasingly higher risks for
all-cause mortality than levels of 12.0 g/dL, whereas HGB levels of 13.0 and 14.0
g/dL were associated with a lower risk of death [ 29 ] .
A study of 755 subjects >85 years of age showed that a HGB <13.0 g/dL in males
and <12.0 g/dL in females was associated with an increased relative risk of
mortality of 1.6 in males (95% CI 1.2-2.1) and 2.3 in females (95% CI 1.6-3.3)
[26 ] . Disorders such as malignancy, peptic ulcer, and infection were more common
in the anemic patients. However, the mortality risk in elderly anemic patients
without obvious clinical disease was also increased to more than twice that of
nonanemic patients.
nonanemic patients.
It was concluded that anemia in older patients is due to disease and not aging, and that
further investigation is warranted if an older person's HGB is below normal, even if no
clinical disease is immediately apparent.
One-third were related to presence of a nutritional deficiency (eg, iron, folate, B12).
Iron deficiency, alone or in combination with folate or B12 deficiency, constituted
more than one-half of this group.
One-third were related to chronic kidney disease and/or other chronic disorders (eg,
arthritis, diabetes, increased serum C-reactive protein, or a positive rheumatoid
factor). ( See "Anemia of chronic disease (anemia of chronic inflammation)" ).
Despite these uncertainties, the most reasonable approach to the anemic elderly patient
consists of ruling out the major identifiable causes, such as bleeding disorders, nutritional
deficiencies, renal disease, inflammatory disorders, and the myelodysplastic syndrome
[37 ] .
Athletes — Values in male and female endurance athletes may vary significantly from
those in otherwise normal people [ 41-46 ] . Dilutional anemia secondary to an increased
plasma volume [ 42,47 ] , gastrointestinal bleeding [ 43 ] , intravascular hemolysis (eg,
march hemoglobinuria) [ 44 ] , iron deficiency [ 48,49 ] , as well as polycythemia [ 45,47 ]
have all been reported as a consequence of strenuous sports, or the use of
performance-enhancing agents, such as androgens and erythropoietin . ( See "Extrinsic
performance-enhancing agents, such as androgens and erythropoietin . ( See "Extrinsic
nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and
hypersplenism" , section on Mechanical trauma and see "Use of androgens and other
drugs by athletes" , section on Androgens and section on Erythropoietin).
Overview — Erythropoiesis in the adult takes place within the bone marrow under the
influence of the stromal framework, cytokines, and the erythroid specific growth factor,
erythropoietin (EPO). EPO is a true endocrine hormone produced in the kidney by cells
that sense the adequacy of tissue oxygenation relative to the individual's metabolic
activity ( show figure 2 ). ( See "Regulation of erythropoiesis" ).
EPO enhances the growth and differentiation of the two erythroid progenitors: burst
forming units-erythroid (BFU-E) and colony forming units-erythroid (CFU-E) into
normoblasts of increasing maturity. When the normoblast extrudes its nucleus to form a
red blood cell, it still has a ribosomal network which, when stained supravitally, identifies
it as a reticulocyte, a cell still capable of a limited amount of hemoglobin and protein
synthesis [ 50 ] .
The reticulocyte retains its ribosomal network (and its staining characteristics) for about
four days, of which three days are generally spent in the marrow and one day in the
peripheral blood ( show figure 3 ). The resulting mature RBC circulates for 110 to 120 days,
after which it is removed from the circulation by macrophages that detect senescent
signals, through mechanisms that are poorly understood.
Under steady state conditions, the rate of RBC production equals the rate of RBC loss.
Assuming, as a first approximation, survival of mature RBC of 100 days, 1 percent of
RBCs are removed from the circulation each day. To achieve a constant RBC mass, RBC
losses must be replaced with an equal number of reticulocytes during the same time
period.
Reticulocytes normally survive in the circulation for one day; after this time they lose their
reticulum (RNA) and become mature red blood cells. Under steady-state conditions
reticulocytes will represent approximately 1 percent of total circulating RBC ( show table 1 ).
Since the normal RBC count is approximately 5 million/microL, the bone marrow must
produce approximately 50,000 reticulocytes/microL of whole blood each day in order to
achieve a stable RBC mass. Lesser rates of RBC production, if persistent, lead to anemia.
The rate of red cell production increases markedly under the influence of high levels of
erythropoietin (EPO). A normal bone marrow replete with iron, folate, and cobalamin can
increase erythropoiesis in response to EPO about 5-fold in adults and 7- to 8-fold in
children. Thus, under optimal conditions, steady-state absolute reticulocyte counts as
high as 250,000/microL are possible in the adult.
Reticulocytes can be counted with more accuracy via automated blood counters after
staining with a fluorescent dye such as thiazole orange, which binds to the RNA of
reticulocytes [ 51 ] . ( See "Automated hematology instrumentation" , section on Automated
counting of reticulocytes).
CLINICAL CONSEQUENCES — The signs and symptoms induced by anemia are dependent
upon the degree of anemia and the rate at which it has evolved, as well as the oxygen
demands of the patient. Symptoms are much less likely with anemia that evolves slowly,
because there is time for multiple homeostatic forces to adjust to a reduced oxygen
carrying capacity of blood. Before discussing these issues, it is helpful to first review the
normal function of red cells.
Normal red cell function — RBCs carry oxygen linked to hemoglobin from the lungs to
tissue capillaries. Oxygen is then released from hemoglobin according to the
characteristics of the oxyhemoglobin dissociation curve, with each gram of hemoglobin
carrying 1.3 mL of oxygen. Thus, approximately 20 mL/dL (or 20 volumes percent) can
be carried by 15 g/dL of hemoglobin at full saturation. Approximately five volumes
percent (25 percent of the total) is normally removed by the tissues [ 52 ] . ( See "Oxygen
delivery and consumption" and see "Genetic disorders of hemoglobin oxygen affinity" ,
section on Mutations that decrease the affinity of hemoglobin for 2,3-DPG).
Symptoms — Symptoms related to anemia can result from two factors: decreased oxygen
delivery to tissues, and, in patients with acute and marked bleeding, the added insult of
hypovolemia. There is some reduction in blood volume but not plasma volume after
acute severe hemolysis, due to the fall in RBC mass. In comparison, total blood volume
remains normal in anemia due to chronic, low-grade bleeding, since there is ample time
for equilibration with the extravascular space and renal retention of salt and water.
Symptoms of impaired oxygen delivery reflect the fall in hemoglobin concentration. The
extraction of oxygen by the tissues can increase from a baseline of 25 percent to a
maximum of about 60 percent in the presence of anemia or hypoperfusion. Thus, normal
oxygen delivery of five volumes percent can be maintained by enhanced extraction alone
down to a hemoglobin concentration of 8 to 9 g/dL [ 53 ] .
When the added compensation of increases in stroke volume and heart rate (and
therefore cardiac output) are included, oxygen delivery can be maintained at rest at a
hemoglobin concentration as low as 5 g/dL (equivalent to a hematocrit of 15 percent),
assuming that the intravascular volume is maintained [ 54 ] . ( See "Indications for red cell
transfusion in the adult" , section on Physiology of anemia).
Symptoms will occur when the hemoglobin concentration falls below this level at rest, at
higher hemoglobin concentrations during exertion, or when cardiac compensation is
impaired because of underlying heart disease. The primary symptoms include exertional
dyspnea, dyspnea at rest, varying degrees of fatigue, and signs and symptoms of the
hyperdynamic state, such as bounding pulses, palpitations, and "roaring in the ears".
More severe anemia may lead to lethargy and confusion and potentially life-threatening
complications such as congestive failure, angina, arrhythmia, and/or myocardial
infarction. ( See "High-output heart failure" ).
A morphologic approach categorizing anemias via alterations in RBC size (ie, mean
corpuscular volume) and the reticulocyte response [ 55 ] .
Kinetic approach — Anemia can be caused by one or more of three independent
mechanisms: decreased RBC production, increased RBC destruction, and blood loss [ 50 ] .
Decreased RBC production — Anemia will ultimately result if the rate of RBC production
is less than that of RBC destruction. ( See "Anemias due to decreased red cell
production" ). The more common causes for reduced (effective) RBC production include:
Lack of nutrients, such as iron, B12, or folate. This can be due to dietary lack,
malabsorption (eg, pernicious anemia, sprue), or blood loss (iron deficiency)
Bone marrow disorders (eg, aplastic anemia, pure RBC aplasia, myelodysplasia,
tumor infiltration)
Low levels of trophic hormones which stimulate RBC production, such as EPO (eg,
chronic renal failure), thyroid hormone (eg, hypothyroidism), and androgens (eg,
hypogonadism). A rare cause of anemia due to reduced EPO production has been
described in patients with autonomic dysfunction and orthostatic hypotension
[56,57 ] . ( See "Treatment of orthostatic and postprandial hypotension" , section on
Erythropoietin ).
Increased RBC destruction — A RBC life span below 100 days is the operational
definition of hemolysis [ 58 ] . ( See "Red blood cell survival: Normal values and
measurement" ). Hemolytic anemia will ensue when the bone marrow is unable to keep up
with the need to replace more than about 5 percent of the RBC mass per day,
corresponding to a RBC survival of about 20 days. ( See "Approach to the diagnosis of
hemolytic anemia in the adult" ).
Bleeding into the upper thigh and/or retroperitoneal space can often be significant,
but may not be clinically obvious. Such patients may, however, have associated
symptoms of abdominal pain or mass, groin or hip pain, leg paresis, or
hypotension [ 59 ] . This complication may be more common in patients taking
anticoagulants, even when results of coagulation tests are within the therapeutic
range. CT imaging of the abdomen and thigh is often helpful if this is suspected.
In addition to the loss of RBCs from the body, which the bone marrow must replace, loss
of the iron contained in these cells will ultimately lead to iron deficiency, once tissue
stores of iron have been depleted. This usually occurs in males and females after losses
of ≥ 1200 mL and ≥ 600 mL, respectively. However, since about 25 percent of menstruant
females have absent iron stores, any amount of bleeding will result in anemia in this
subpopulation. ( See "Causes and diagnosis of anemia due to iron deficiency" ).
Since availability of iron is normally rate-limiting for RBC production, iron deficiency
associated with chronic bleeding leads to a reduced marrow response, worsening the
degree of anemia.
Automatic cell counters estimate RBC volume cell by cell, sampling millions of RBCs in the
process. ( See "Mean corpuscular volume" ). Machine output is a value for the mean
corpuscular volume of the sample (MCV), as well as an estimate of the dispersion of
values about this mean. The latter value is usually given as the coefficient of variation of
RBC volumes or RBC distribution width (RDW).
An increased RDW indicates the presence of cells of widely differing sizes, but it is not
diagnostic of any particular disorder. However, some automatic cell counters have
computer programs which "flag" for the presence of abnormalities such as anisocytosis
(cells of varying size), microcytosis, macrocytosis, and hypochromia (reduced hemoglobin
content per cell) [ 61 ] . ( See "Automated hematology instrumentation" , section on Red
cell distribution width).
Other common causes include alcohol abuse, liver disease, and hypothyroidism.
A report from a family practice group found macrocytosis in 2 to 4 percent of patients [ 62 ]
, while a study of 1,784 randomly selected elderly people living at home found
macrocytosis in 6.3 percent of men and 3.3 percent of women [ 63 ] . The most common
causes were alcoholism, liver disease, hypothyroidism, and the megaloblastic anemias.
Reduced iron availability — severe iron deficiency, the anemia of chronic disease,
copper deficiency
The three most common causes of microcytosis in clinical practice are iron deficiency,
alpha or beta thalassemia minor, and (less often) the anemia of chronic disease (anemia
of chronic inflammation). Since all may have hypochromic and microcytic RBCs, other
tests must be used to establish the diagnosis.
Iron deficiency anemia — Important discriminating features are a low serum ferritin
concentration, an increased total iron binding capacity (transferrin), and low serum
iron concentration ( show table 6 ). For some physicians, proof of this diagnosis
requires a clinical response (ie, increase in HGB or HCT) to treatment with iron.
For physicians making this diagnosis, it is mandatory to determine the cause of the iron
deficient state (eg, occult colonic carcinoma, excessive menstrual losses). ( See "Causes
and diagnosis of anemia due to iron deficiency" ).
Alpha or beta thalassemia minor — Adults with thalassemia are most often
heterozygotes for the alpha or beta forms of this syndrome, and may not be
anemic. A family history is therefore often negative. Physical examination may
reveal splenomegaly; the peripheral smear shows varying degrees of hypochromia,
microcytosis, target cells ( show blood smear 4 ), tear-drop forms, and basophilic
stippling ( show blood smear 5 ). The RBC count may actually be increased and
uncomplicated patients have normal or increased iron stores. ( See "Clinical
manifestations and diagnosis of the thalassemias" ).
The diagnosis of beta thalassemia trait can often be made by demonstrating increased
levels of hemoglobin A2 on hemoglobin electrophoresis or liquid chromatography (HPLC),
while molecular methods are usually required for the diagnosis of mild alpha thalassemia
variants [ 64 ] . ( See "Molecular diagnosis of inherited hemoglobin disorders" ).
variants [ 64 ] . ( See "Molecular diagnosis of inherited hemoglobin disorders" ).
Initial approach — Anemia is one of the major signs of disease. It is never normal and its
cause(s) should always be sought. The history, physical examination, and simple
laboratory testing are all useful in evaluating the anemic patient. The workup should be
directed towards answering the following questions concerning whether one or more of the
major processes leading to anemia may be operative:
Is there a history of, or symptoms related to, a medical condition which is known to
result in anemia (eg, tarry stools in a patient with ulcer-type pain, rheumatoid
arthritis, renal failure)?
Physical examination — The major aim on physical examination is to find signs of organ
or multisystem involvement and to assess the severity of the patient's condition. Thus,
the presence or absence of tachycardia, dyspnea, fever, or postural hypotension should
be noted. While evaluation for jaundice and pallor is a standard part of the physical
examination, such signs may be misinterpreted, and are not as reliable indicators of
anemia as once thought.
Pallor — The sensitivity and specificity for pallor in the palms, nail beds, face, or
conjunctivae as a predictor for anemia varies from 19 to 70 percent and 70 to 100
percent, respectively [ 66-69 ] , with wide interobserver differences and widely differing
conclusions as to the clinical value of the presence or absence of this finding.
Other items to search for on physical examination include the presence or absence of
lymphadenopathy, hepatosplenomegaly, and bone tenderness, especially over the
sternum. Bone pain may signify expansion of the marrow space due to infiltrative
disease, as in chronic myelogenous leukemia, or lytic lesions as in multiple myeloma or
metastatic cancer.
Many automated blood counters report a RBC distribution width (RDW), a measure of the
degree of variation in red cell size ( red cell volume, see "Morphologic approach" above ).
However, the RDW alone does not indicate why the RBC size varies (anisocytosis) or what
the RBC shapes are (poikilocytosis). Some counters will "flag" for the presence of specific
RBC changes, such as hypochromia or microcytosis, which can be confirmed by
RBC changes, such as hypochromia or microcytosis, which can be confirmed by
examination of the peripheral smear. ( See "Automated hematology instrumentation" ).
Red blood cell indices — Three RBC indices are usually measured by automated blood
counters: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and
mean corpuscular hemoglobin concentration (MCHC) ( show table 1 ). The values for MCH
and MCHC generally parallel the information obtained from the MCV (ie, larger or smaller
RBCs tend to have higher or lower values for MCH, respectively).
Mean corpuscular volume — The normal range for MCV is from 80 to 100 femtoliters
(fL). The causes of anemia associated with a low (microcytosis) or high (macrocytosis)
MCV are discussed above ( show table 4 , see "Morphologic approach" above ). Values in
excess of 115 fL are almost exclusively seen in vitamin B12 or folic acid deficiency. Even
higher values can occur as an artifact when cold agglutinins are present, which causes
RBCs to go through the counting aperture in doublets or triplets [ 72 ] . Warming the
specimen (and reagents) to body temperature prior to a repeat count should return the
MCV to normal, and confirm the presence of a cold agglutinin. ( See "Mean corpuscular
volume" ).
Mean corpuscular hemoglobin — The normal MCH ranges from 27.5 to 33.2 picograms
of hemoglobin per RBC. Low values are seen in iron deficiency and thalassemia, while
increased values occur in macrocytosis of any cause.
Mean corpuscular hemoglobin concentration — The mean normal value for the MCHC
is 34 grams of hemoglobin per dL of RBCs. The 95 percent confidence limits for the
MCHC have been variably given ( show table 1 ), with lower and upper limits of 31 to 33
and 35 to 36, respectively. Low values occur in the same conditions that generate low
values for MCV and MCH, while increased values occur almost exclusively in the presence
of congenital or acquired spherocytosis or in other congenital hemolytic anemias in which
red cells are abnormally dessicated (eg, sickle cell anemia, hemoglobin C disease,
xerocytosis). ( See "Hereditary spherocytosis: Clinical features; diagnosis; and treatment"
and see "Xerocytosis" ).
Reticulocyte count — The reticulocyte count, either as a percentage of all RBCs, the
absolute reticulocyte count, the corrected absolute reticulocyte count, or as the reticulocyte
production index, helps to distinguish among the different types of anemia:
A stable anemia with a low reticulocyte count is strong evidence for deficient
production of RBCs (ie, a reduced marrow response to the anemia). ( See "Anemias
due to decreased red cell production" ).
Hemolysis or blood loss can be associated with a low reticulocyte count if there is a
concurrent disorder that impairs RBC production (eg, infection, prior chemotherapy;
see "Multiple causes of anemia" below ).
Clues to the specific abnormality present may be obtained from the WBC differential,
which, in conjunction with the total WBC may show increased or decreased absolute
numbers of the various cell types in the circulation. Examples include:
However, in one study of 100 subjects with normal values for red cell folate and serum
cobalamin, NH (as defined above) was seen in 62 and 4 percent of 50 iron deficient and
50 normal subjects, respectively [ 73 ] . The mechanism for NH in iron deficiency is
unknown.
Circulating nucleated red blood cells — Nucleated RBCs (NRBCs) are not normally found in
the circulation. They may be present in patients with known hematologic disease (eg,
sickle cell disease, thalassemia major, various hemolytic anemias after splenectomy), or
as a part of the leukoerythroblastic pattern seen in patients with bone marrow
replacement ( show blood smear 8 ).
In patients without known hematologic disease, NRBCs may reflect the presence of a
life-threatening disease, such as sepsis or severe heart failure. In one study of 4,173
patients seen at a university clinic, NRBCs were seen at least once in 7.5 percent of all
patients; the highest incidence (20 percent) occurred in patients from the general surgery
and trauma intensive care unit [ 74 ] . In-hospital mortality was 1.2 and 21.1 percent in
those without or with NRBCs, respectively, and increased with increasing concentration of
NRBCs. In patients who died, nucleated RBCs were detected for the first time at a median
of 13 days before death.
Platelet count — Abnormalities in the platelet count often provide important diagnostic
information. Thrombocytopenia occurs in a variety of disorders associated with anemia,
including hypersplenism, marrow involvement with malignancy, autoimmune platelet
destruction (either idiopathic or drug-related), sepsis, or folate or cobalamin deficiency.
High platelet counts, in comparison, may reflect myeloproliferative disease, chronic iron
deficiency, and inflammatory, infectious, or neoplastic disorders. ( See "Approach to the
patient with thrombocytosis" ). Changes in platelet morphology (giant platelets,
degranulated platelets) also may be important, suggesting myeloproliferative or
myelodysplastic disease.
Mild degrees of pancytopenia may be seen in patients with splenomegaly and splenic
trapping of circulating cellular elements. ( See "Extrinsic nonimmune hemolytic anemia
due to mechanical damage: Fragmentation hemolysis and hypersplenism" , section on
Extravascular nonimmune hemolysis due to hypersplenism).
Blood smear — Many clinicians rely on the above RBC parameters and the RDW in
evaluating a patient with anemia. However, the RDW is, as noted above, of limited utility,
and examination of the peripheral blood smear provides information not otherwise
available. ( See "Evaluation of the peripheral blood smear" ).
As examples, the automated counter may miss the red cell fragmentation ("helmet
cells", schistocytes) of microangiopathic hemolysis ( show blood smear 9 ),
microspherocytes in autoimmune hemolytic anemia, teardrop RBCs in myeloid metaplasia
(show blood smear 10 ), a leukoerythroblastic pattern with bone marrow replacement
(show blood smear 8 ), the "bite cells" in oxidative hemolysis ( show blood smear 11 ), or
RBC parasites such as malaria or babesiosis ( show blood smear 12 ). ( See "Evaluation of
the peripheral blood smear" ).
Serial evaluation of hemoglobin and hematocrit — Measuring the rate of fall of the
patient's HGB or HCT often provides helpful diagnostic information. Suppose the HGB
concentration has fallen from 15 to 10 g/dL in one week. If this were due to total
cessation of RBC production (ie, a reticulocyte count of zero) and if the rate of RBC
destruction were normal (1 percent/day), the HGB concentration would have fallen by 7
percent over seven days, resulting a decline of 1.05 g/dL (0.07 x 15). The greater fall in
HGB in this patient (5 g/dL) indicates that marrow suppression cannot be the sole cause
of the anemia and that blood loss and/or increased RBC destruction must be present.
Evaluation for iron deficiency — More complete evaluation for iron deficiency is indicated
when the history (menometrorrhagia, symptoms of peptic ulcer disease) and preliminary
laboratory data (low MCV, low MCH, high RDW, increased platelet count) support this
diagnosis. In this setting, the plasma levels of iron, iron binding capacity (transferrin),
transferrin saturation, and ferritin should be measured ( show table 6 ). ( See "Causes and
diagnosis of anemia due to iron deficiency" ).
Evaluation for hemolysis — Hemolysis should be considered if the patient has a rapid fall
in hemoglobin concentration, reticulocytosis, and/or abnormally shaped RBC (especially
spherocytes or fragmented RBCs) on the peripheral smear ( show table 3 ). The usual
ancillary findings of hemolysis are an increase in the serum lactate dehydrogenase (LDH)
and indirect bilirubin concentrations and a reduction in the serum haptoglobin
concentration. ( See "Approach to the diagnosis of hemolytic anemia in the adult" ).
The combination of an increased LDH and reduced haptoglobin is 90 percent specific for
diagnosing hemolysis, while the combination of a normal LDH and a serum haptoglobin
greater than 25 mg/dL is 92 percent sensitive for ruling out hemolysis [ 75,76 ] .
Bone marrow examination — Examination of the bone marrow generally offers little
additional diagnostic information in the more common forms of anemia. If erythropoiesis
is increased in response to the anemia, the bone marrow will show erythroid hyperplasia,
a nonspecific finding. Similarly, although the absence of stainable iron in the bone
a nonspecific finding. Similarly, although the absence of stainable iron in the bone
marrow had previously been considered the "gold standard" for the diagnosis of iron
deficiency, this diagnosis is usually established by laboratory tests alone ( show table 6 ).
(See "Causes and diagnosis of anemia due to iron deficiency" , section on Diagnosis).
Indications for examination of the bone marrow in anemic patients include pancytopenia
or the presence of abnormal cells in the circulation, such as blast forms. Such patients
may have aplastic anemia, myelodysplasia, marrow replacement with malignancy, or a
myeloproliferative disease. Other findings that may be seen in the marrow in anemic
patients include megaloblastic erythropoiesis (folate or cobalamin deficiency), absence of
recognizable RBC precursors (pure RBC aplasia), vacuolization of RBC precursors (alcohol
or drug-induced anemia), and increased iron-laden RBC precursors (the sideroblastic
anemias). ( See "Evaluation of bone marrow aspirate smears" ).
A patient with gastrointestinal bleeding secondary to colon cancer may also have
the anemia of chronic disease, leading to a blunted reticulocyte response. ( See
"Anemia of chronic disease (Anemia of chronic inflammation)" ).
A patient with a chronic hemolytic anemia (eg, sickle cell anemia, hereditary
spherocytosis) may develop worsening anemia following acute infection, particularly
with parvovirus B19, which may blunt or temporarily ablate erythropoiesis and the
reticulocyte response [ 77 ] . ( See "Acquired pure red cell aplasia" , section on
Etiology and pathogenesis).
A patient with autoimmune hemolytic anemia may develop worsening anemia from
gastrointestinal blood loss following treatment with corticosteroids .
Anemia, renal failure, and congestive failure are often found together, a condition
that has been termed "cardio-renal anemia syndrome." Treatment of the anemia
may improve both the renal failure and heart failure [ 78 ] . ( See "Anemia and left
ventricular hypertrophy in chronic kidney disease" ).
Algorithms for diagnosing anemia ( show algorithm 1 ) generally fail in the presence of
more than one cause. Under such circumstances, the clinician is advised to obtain
answers separately to each of the questions outlined above ( see "Initial approach"
above ), to examine the peripheral blood smear for abnormal red blood cell populations
(eg, microcytes, macrocytes, spherocytes, schistocytes), and proceed from that point.
INFORMATION FOR PATIENTS — Educational materials on this topic are available for
patients. ( See "Patient information: Iron deficiency anemia" ). We encourage you to print
or e-mail this topic review, or to refer patients to our public web site,
www.uptodate.com/patients , which includes this and other topics.
The anemia is first classified via the mean corpuscular volume (MCV), which is part of the
CBC ( show algorithm 1 ):
Microcytic anemias are associated with an MCV below 80 fL. The most commonly
seen causes are iron deficiency ( show table 4 and show table 6 ), thalassemia, and
seen causes are iron deficiency ( show table 4 and show table 6 ), thalassemia, and
the anemia of chronic disease ( see "Microcytic anemia" above and see "Evaluation
for iron deficiency" above ).
Macrocytic anemias are characterized by an MCV above 100 fL ( show table 4 and
show table 5 ). The most common causes include alcoholism, liver disease, folic acid
and vitamin B12 deficiency, and myelodysplasia. ( See "Macrocytosis" , section on
Evaluation).
The MCV is between 80 and 100 fL in patients with normocytic anemia ( show table
4). This is an extremely large and amorphous category, which can be narrowed
somewhat by examination of the blood smear to determine if there is a small
population of red cells with distinctive size or shape abnormalities which would place
the patient in one of the above categories (ie, EARLY microcytic or macrocytic
anemia), or would raise suspicion of an acute or chronic hemolytic state (eg,
spherocytes, sickle forms, ovalocytes).
Hemolysis may have been suspected from the patient's history and physical
examination (eg, sudden onset of anemia, jaundice, splenomegaly; see
"Evaluation of the patient" above ). It is confirmed by the finding of increased levels
of indirect bilirubin and lactate dehydrogenase, and low levels of haptoglobin ( show
table 3 ). ( See "Evaluation for hemolysis" above and see "Approach to the diagnosis
of hemolytic anemia in the adult" , section on Diagnostic approach).
The presence of abnormal cells in the circulation (eg, nucleated RBCs, blasts,
atypical mononuclear cells) and/or abnormal increases or decreases in absolute
counts for granulocytes, lymphocytes, monocytes, or platelets ( show algorithm 1 )
suggests that the anemia is part of a more complex hematologic disorder (eg,
leukemia, aplastic anemia, myelodysplastic syndrome, myeloproliferative disorder).
Consultation with a hematologist would be appropriate at this point.
Anemia may be the first manifestation of a systemic disorder ( show table 4 ), along with
other nonspecific complaints such as fever, weight loss, anorexia, and malaise. Simple
laboratory tests may give additional clues toward the underlying disease process. These
include abnormalities on the urinalysis or routine chest x-ray, elevated serum creatinine,
abnormal liver function tests, and increased erythrocyte sedimentation rate.
REFERENCES
1. Beutler, E, Waalen, J. The definition of anemia: what is the lower limit of normal of
the blood hemoglobin concentration?. Blood 2006; 107:1747.
2. World Health Organization. Nutritional anaemias: Report of a WHO scientific group.
Geneva, Switzerland: World Health Organization; 1968.
3. Rodgers, GM, Becker, PS, Bennett, CL, et al. Cancer- and chemotherapy-induced
anemia. J Natl Compr Canc Netw 2008; 6:536.
4. Culleton, BF, Manns, BJ, Zhang, J, et al. Impact of anemia on hospitalization and
mortality in older adults. Blood 2006; 107:3841.
5. Patel, KV, Harris, TB, Faulhaber, M, et al. Racial variation in the relationship of
anemia with mortality and mobility disability among older adults. Blood 2007; :.
6. Jacob, G, Raj, SR, Ketch, T, et al. Postural pseudoanemia: posture-dependent
change in hematocrit. Mayo Clin Proc 2005; 80:611.
7. Valeri, CR, Dennis, RC, Ragno, G, et al. Limitations of the hematocrit level to
7. Valeri, CR, Dennis, RC, Ragno, G, et al. Limitations of the hematocrit level to
assess the need for red blood cell transfusion in hypovolemic anemic patients.
Transfusion 2006; 46:365.
8. Ruiz-Arguelles, GJ, Beutler, E, Waalen, J. Altitude above sea level as a variable for
definition of anemia. Blood 2006; 108:2131.
9. Stewart, RD, Baretta, ED, Platte, LR, et al. Carboxyhemoglobin levels in American
blood donors. JAMA 1974; 229:1187.
10. Nordenberg, D, Yip, R, Binkin, NJ. The effect of cigarette smoking on hemoglobin
levels and anemia screening. JAMA 1990; 264:1556.
11. Garn, SM, Ryan, AS, Abraham, S, Owen, G. Suggested sex and age appropriate
values for "low" and "deficient" hemoglobin levels. Am J Clin Nutr 1981; 34:1648.
12. Reed, WW, Diehl, LF. Leukopenia, neutropenia, and reduced hemoglobin levels in
healthy American blacks. Arch Intern Med 1991; 151:501.
13. Perry, GS, Byers, T, Yip, R, Margen, S. Iron nutrition does not account for the
hemoglobin differences between blacks and whites. J Nutr 1992; 122:1417.
14. Denny, SD, Kuchibhatla, MN, Cohen, HJ. Impact of anemia on mortality, cognition,
and function in community-dwelling elderly. Am J Med 2006; 119:327.
15. Robins, EB, Blum, S. Hematologic reference values for African American children and
adolescents. Am J Hematol 2007; 82:611.
16. Beutler, E, West, C. Hematologic differences between African-Americans and whites:
the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean
corpuscular volume. Blood 2005; 106:740.
17. Nilsson-Ehle, H, Jagenburg, R, Landahl, S, et al. Haematological abnormalities and
reference intervals in the elderly. A cross-sectional comparative study of three urban
Swedish population samples aged 70, 75 and 81 years. Acta Med Scand 1988;
224:595.
18. Nilsson-Ehle, H, Jagenburg, R, Landahl, S, et al. Decline of blood haemoglobin in
the aged: a longitudinal study of an urban Swedish population from age 70 to 81.
Br J Haematol 1989; 71:437.
19. Patel, KV. Epidemiology of anemia in older adults. Semin Hematol 2008; 45:210.
20. Guralnik, JM, Eisenstaedt, RS, Ferrucci, L, et al. Prevalence of anemia in persons 65
years and older in the United States: evidence for a high rate of unexplained
anemia. Blood 2004; 104:2263.
21. Beghe, C, Wilson, A, Ershler, WB. Prevalence and outcomes of anemia in geriatrics:
a systematic review of the literature. Am J Med 2004; 116 Suppl 7A:3S.
22. den Elzen, WP, Westendorp, RG, Frolich, M, et al. Vitamin B12 and folate and the
risk of anemia in old age: the Leiden 85-Plus Study. Arch Intern Med 2008;
168:2238.
23. Baldwin, JG. Hematopoietic function in the elderly. Arch Intern Med 1988; 148:2544.
24. Balducci, L. Epidemiology of anemia in the elderly: information on diagnostic
evaluation. J Am Geriatr Soc 2003; 51:2.
25. Penninx, BW, Guralnik, JM, Onder, G, et al. Anemia and decline in physical
performance among older persons. Am J Med 2003; 115:104.
26. Izaks, GJ, Westendorp, RGJ, Knook, DL. The definition of anemia in older persons.
JAMA 1999; 281:1714.
27. Nissenson, AR, Goodnough, LT, Dubois, RW. Anemia: not just an innocent
bystander?. Arch Intern Med 2003; 163:1400.
28. Artz, AS, Fergusson, D, Drinka, PJ, et al. Mechanisms of unexplained anemia in the
nursing home. J Am Geriatr Soc 2004; 52:423.
29. Chaves, PH, Xue, QL, Guralnik, JM, et al. What constitutes normal hemoglobin
concentration in community-dwelling disabled older women?. J Am Geriatr Soc 2004;
52:1811.
52:1811.
30. Patel, KV, Harris, TB, Faulhaber, M, et al. Racial variation in the relationship of
anemia with mortality and mobility disability among older adults. Blood 2007;
109:4663.
31. Herzog, CA, Muster, HA, Li, S, Collins, AJ. Impact of congestive heart failure, chronic
kidney disease, and anemia on survival in the Medicare population. J Card Fail
2004; 10:467.
32. Adamson, JW. Renal disease and anemia in the elderly. Semin Hematol 2008;
45:235.
33. Gazit, R, Weissman, IL, Rossi, DJ. Hematopoietic stem cells and the aging
hematopoietic system. Semin Hematol 2008; 45:218.
34. Ble, A, Fink, JC, Woodman, RC, et al. Renal function, erythropoietin, and anemia of
older persons: the InCHIANTI study. Arch Intern Med 2005; 165:2222.
35. Ferrucci, L, Maggio, M, Bandinelli, S, et al. Low testosterone levels and the risk of
anemia in older men and women. Arch Intern Med 2006; 166:1380.
36. Ferrucci, L, Guralnik, JM, Bandinelli, S, et al. Unexplained anaemia in older persons
is characterised by low erythropoietin and low levels of pro-inflammatory markers.
Br J Haematol 2007; 136:849.
37. Steensma, DP, Tefferi, A. Anemia in the elderly: How should we define it, when
does it matter, and what can be done?. Mayo Clin Proc 2007; 82:958.
38. Makipour, S, Kanapuru, B, Ershler, WB. Unexplained anemia in the elderly. Semin
Hematol 2008; 45:250.
39. Agarwal, N, Prchal, JT. Erythropoietic agents and the elderly. Semin Hematol 2008;
45:267.
40. Agnihotri, P, Telfer, M, Butt, Z, et al. Chronic anemia and fatigue in elderly patients:
results of a randomized, double-blind, placebo-controlled, crossover exploratory
study with epoetin alfa. J Am Geriatr Soc 2007; 55:1557.
41. Dufaux, B, Hoederath, A, Streitberger, I, et al. Serum ferritin, transferrin,
haptoglobin and iron in middle-and long-distance runners, elite rowers and
professional racing cyclists. Int J Sports Med 1981; 2:43.
42. Shaskey, DJ, Green, GA. Sports haematology. Sports Med 2000; 29:27.
43. Rudzki, SJ, Hazard, H, Collinson, D. Gastrointestinal blood loss in triathletes: Its
etiology and relationship to sports anaemia. Aust J Sci Med Sport 1995; 27:3.
44. Selby, GB, Eichner, ER. Endurance swimming, intravascular hemolysis, anemia and
iron depletion. Am J Med 1986; 81:791.
45. Berglund, B. High-altitude training. Aspects of haematological adaptation. Sports
Med 1992; 14:289.
46. Kehat, I, Shupak, A, Goldenberg, I, Shoshani, O. Long-term hematological effects
in Special Forces trainees. Mil Med 2003; 168:116.
47. Sawka, MN, Convertino, VA, Eichner, ER, et al. Blood volume: importance and
adaptations to exercise training, environmental stresses, and trauma/sickness. Med
Sci Sports Exerc 2000; 32:332.
48. Greydanus, DE, Patel, DR. The female athlete. Before and beyond puberty. Pediatr
Clin North Am 2002; 49:553.
49. Beard, J, Tobin, B. Iron status and exercise. Am J Clin Nutr 2000; 72:594S.
50. Hillman, RS, Ault, KA (Eds). Clinical approach to anemia. In: Hematology in Clinical
Practice, McGraw-Hill, New York 2001. p.29.
51. Erslev, AJ. Reticulocyte enumeration. In: Williams' Hematology, 5th ed, Beutler, E,
Lichtman, MA, Coller, BS, et al (Eds), McGraw-Hill, New York 1995. p.L28.
52. Hillman, RS, Ault, KA (Eds). Normal erythropoiesis. In: Hematology in Clinical
Practice, McGraw-Hill, New York 2001. p.3.
53. Jones, J. Transfusion in oligemia. In: Blood Transfusion in Clinical Medicine, 8th ed,
53. Jones, J. Transfusion in oligemia. In: Blood Transfusion in Clinical Medicine, 8th ed,
Mollison, PL, Engelfriet, CP, Contreras, M (Eds), Blackwell, Oxford 1987. p.41.
54. Weiskopf, RB, Viele, MK, Feiner, J, et al. Human cardiovascular and metabolic
response to acute, severe isovolemic anemia. JAMA 1998; 279:217.
55. Tefferi, A. Anemia in adults: A contemporary approach to diagnosis. Mayo Clin Proc
2003; 78:1274.
56. Gomes, ME, Deinum, J, Timmers, HJ, Lenders, JW. Occam's razor; anaemia and
orthostatic hypotension. Lancet 2003; 362:1282.
57. Perera, R, Isola, L, Kaufmann, H. Effect of recombinant erythropoietin on anemia
and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995;
5:211.
58. Mohandas, N, Schrier, SL. Mechanisms of red cell destruction in hemolytic anemias.
In: The Hereditary Hemolytic Anemias, Mentzer, WC, Wagner, GM (Eds), Churchill
Livingstone, New York 1989. p.391.
59. Gonzalez, C, Penado, S, Llata, L, et al. The clinical spectrum of retroperitoneal
hematoma in anticoagulated patients. Medicine (Baltimore) 2003; 82:257.
60. Bull, BS, Breton-Gorius, J. Morphology of the erythron. In: Williams' Hematology,
5th ed, Beutler, E, Lichtman, MA, Coller, BS, Kipps, TJ (Eds), McGraw-Hill, New York.
p.349.
61. Morris, MW, Williams, WJ, Nelson, DA. Automated blood cell counting. In: Williams'
Hematology, 5th ed, Beutler, E, Lichtman, MA, Coller, BS, et al (Eds), McGraw-Hill,
New York 1995. p.L3.
62. Davenport, J. Macrocytic anemia. Am Fam Physician 1996; 53:155.
63. Inelmen, EM, D'Alessio, M, Gatto, MR, et al. Descriptive analysis of the prevalence
of anemia in a randomly selected sample of elderly people living at home: some
results of an Italian multicentric study. Aging (Milano) 1994; 6:81.
64. Bergstrome Jones, AK, Poon, A. Evaluation of a single-tube multiplex polymerase
chain reaction screen for detection of common alpha-thalassemia genotypes in a
clinical laboratory. Am J Clin Pathol 2002; 118:18.
65. Steensma, DP, Hoyer, JD, Fairbanks, VF. Hereditary red blood cell disorders in
Middle Eastern patients. Mayo Clin Proc 2001; 76:285.
66. Nardone, DA, Roth, KM, Mazur, DJ, et al. Usefulness of physical examination in
detecting the presence or absence of anemia. Arch Intern Med 1990; 150:201.
67. Gjorup, T, Bugge, PM, Hendriksen, C, Jensen, AM. A critical evaluation of the clinical
diagnosis of anemia. Am J Epidemiol 1986; 124:657.
68. Hung, OL, Kwon, NS, Cole, AE, et al. Evaluation of the physician's ability to
recognize the presence or absence of anemia, fever, and jaundice. Acad Emerg Med
2000; 7:146.
69. Sheth, TN, Choudhry, NK, Bowes, M, Detsky, AS. The relation of conjunctival pallor
to the presence of anemia. J Gen Intern Med 1997; 12:102.
70. Ruiz, MA, Saab, S, Rickman, LS. The clinical detection of scleral icterus:
Observations of multiple examiners. Mil Med 1997; 162:560.
71. Williams, WJ, Morris, MW, Nelson, DA. Examination of the blood. In: Williams'
Hematology, 5th ed, Beutler,E, Lichtman, MA, Coller, BS, et al (Eds), McGraw-Hill,
New York, 1995, p. 8.
72. Weiss, GB, Bessman, JD. Spurious automated red cell values in warm autoimmune
hemolytic anemia. Am J Hematol 1984; 17:433.
73. Westerman, DA, Evans, D, Metz, J. Neutrophil hypersegmentation in iron deficiency
anaemia: a case-control study. Br J Haematol 1999; 107:512.
74. Stachon, A, Sondermann, N, Imohl, M, Krieg, M. Nucleated red blood cells indicate
high risk of in-hospital mortality. J Lab Clin Med 2002; 140:407.
75. Marchand, A, Galen, RS, Van Lente, F. The predictive value of serum haptoglobin in
75. Marchand, A, Galen, RS, Van Lente, F. The predictive value of serum haptoglobin in
hemolytic disease. JAMA 1980; 243:1909.
76. Galen, RS. Application of the predictive value model in the analysis of test
effectiveness. Clin Lab Med 1982; 2:685.
77. Serjeant, GR, Serjeant, GE, Thomas, PW, et al. Human parvovirus infection in
homozygous sickle cell disease. Lancet 1993; 341:1237.
78. Silverberg, DS, Wexler, D, Iaina, A, Schwartz, D. The interaction between heart
failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006;
26:296.
GRAPHICS
Manual hematocrit
Normal values for red blood cell parameters in men and women
Adult Adult
Red cell parameter men women
Hemoglobin, g/dL 15.7 ± 1.7 13.8 ± 1.5
88.0 ±
Mean corpuscular volume, fL
8.0
30.4 ±
Mean cell hemoglobin, pg/RBC
2.8
Mean cell hemoglobin concentration, g/dL 34.4 ±
of RBC 1.1
20-59 13.7
60+ 13.2
White women, y
20-49 12.2
50+ 12.2
Black men, y
20-59 12.9
60+ 12.7
Black women, y
20-49 11.5
50+ 11.5
Based on Scripps-Kaiser data for the 5th percentiles given in Table 2. NHANES data
are considered to be confirmatory. To convert hemoglobin from grams per deciliter
to grams per liter, multiply grams per deciliter by 10. Reproduced from: Beutler, E,
Waalen, J. The definition of anemia: what is the lower limit of normal of the blood
hemoglobin concentration? Blood 2006; 107:1747. Copyright ©2006 The American
Society of Hematology.
Polychromatophilia
Liver disease
Hypersplenism
Snake bites
Thalassemic disorders
Aplastic anemia
Endocrine dysfunction
Hypothyroidism
Hypopituitarism
Myelodysplastic syndromes
Reticulocytosis
Hemolytic anemia
Liver disease
This list is not meant to be exhaustive; only the most common causes are
mentioned. In addition, two or more of these conditions may be present (eg,
combined iron and folic acid deficiencies), resulting in a misleadingly normal mean
corpuscular volume.
Folate deficiency
Drugs
Hydroxyurea
Zidovudine
Cytosine arabinoside
Methotrexate
Azathioprine or 6-mercaptopurine
Cladribine
Capecitabine
Imatinib, sunitinib
Lipid abnormalities
Liver disease
Hypothyroidism
Hyperlipidemia
Mechanism unknown
Alcohol abuse
Fe Fe Severe Fe
deficiency deficiency deficiency
without with mild with severe
Normal anemia anemia anemia
Marrow reticulo-
2+ to 3+ None None None
endothelial iron
Iron binding
capacity 300 to
300 to 390 350 to 400 >410
(transferrin), 360
µg/dL
Saturation
20 to 50 30 <15 <10
(SI/TIBC), percent
Hemoglobin, g/dL Normal Normal 9 to 12 6 to 7
Normal or
Red cell Hypochromia
Normal Normal slight
morphology and microcytosis
hypochromia
Plasma or serum
40 to 200 <40 <20 <10
ferritin, ng/mL
Erythrocyte
protoporphyrin, 30 to 70 30 to 70 >100 100 to 200
ng/mL RBC
Nail and
Other tissue
None None None epithelial
changes
changes
Note: Test results outlined in bold type are the ones most likely to define the various
stages of iron deficiency. Thus, the presence or absence of iron stores (marrow
reticuloendothelial iron) in a non-anemic patient serves to distinguish normal subjects
from those with iron deficiency without anemia, respectively.
Basophilic stippling
Hypersegmented neutrophil
Leukoerythroblastic smear
Microangiopathic smear
Teardrop cells
Malaria
Adapted from Nathan, DG, Oski, FA. Hematology of Infancy and Childhood, 4th ed,
WB Saunders, Philadelphia, PA 1993. p. 352.
© 2009 UpToDate, Inc. All rights reserved. | Subscription and License Agreement